Director and 10% owner of Repro-Med Systems, Joseph Manko Jr., purchased 136,248 shares of Repro-Med Systems (REPR, Financial) in late September, according to a Form 4Â filing with the Securities and Exchange Commission. The purchase came in two transactions.
On Sept. 29, Manko purchased 30,500 shares of the company at 42 cents per share. Then on Sept. 30, he added an additional 105,748 shares at 45 cents per share. Since the purchases, Repro-Med Systems' market price has declined by an estimated -2.27%.
Repro-Med Systems has a market cap of $16.51 million, an enterprise value of $12.84 million, a price-earnings (P/E) ratio of 44 and a price-book (P/B) ratio of 2.40.
Repro-Med Systems was incorporated in New York in 1980. The company designs, manufactures and markets proprietary and innovative medical devices primarily for the ambulatory infusion market and emergency medical applications. The company’s products include the FREEDOM60 Syringe Infusion System and accessories, RMS HIgH-Flo Subcutaneous Safety Needle Sets and the RES-Q-VAC Portable Medical Suction System. Repro-Med Systems infusion delivery system is improving the quality of life for more than 15,000 patients around the world, according to the company’s most recent 10-K filing.
According to GuruFocus, Repro-Med Systems has a 9 of 10 financial strength rating with no debt. The company also has a 0.83 equity to asset ratio and an interest coverage of 68.46. The Piotroski F-Score of 8 indicates a very healthy situation and the Beneish M-Score of -3.23 indicates the company is not a manipulator of its financial statements. GuruFocus also gives the company an 8 of 10 profitability and growth rating with an operating margin of 7.06%, a net-margin of 4.88%, a ROE of 9.15%, a ROA of 7.68% and three-year revenue growth of 14.40%.
Manko has over 20 years of investment experience. Before beginning his investment banking career, he was a corporate finance attorney at Skadden, Arps, Slate, Meagher & Flom. He has served on the board of several European companies, participated in numerous successful shareholder value creation strategies and helped companies raise substantial amounts of growth capital.
Disclosure:Â Author does not own any shares of this company.
Start a free 7-day trial of Premium Membership to GuruFocus.
